RACK7 Antibodies

Target Information

Chromatin reader that recognizes dual histone modifications such as histone H3.1 dimethylated at 'Lys-36' and histone H4 acetylated at 'Lys-16' (H3.1K36me2-H4K16ac) and histone H3 methylated at 'Lys-4' and histone H4 acetylated at 'Lys-14' (H3K4me1-H3K14ac). May act as a transcriptional corepressor for KDM5D by recognizing the dual histone signature H3K4me1-H3K14ac. May also act as a transcriptional corepressor for KDM5C and EZH2. Recognizes acetylated histone H4 and recruits the NuRD chromatin remodeling complex to damaged chromatin for transcriptional repression and double-strand break repair by homologous recombination. Also activates transcription elongation by RNA polymerase II through recruiting the P-TEFb complex to target promoters. Localizes to H3.1K36me2-H4K16ac marks at all-trans-retinoic acid (ATRA)-responsive genes and positively regulates their expression. Promotes neuronal differentiation by associating with regulatory regions within the MAPT gene, to enhance transcription of a protein-coding MAPT isoform and suppress the non-coding MAPT213 isoform. Suppresses breast cancer, and prostate cancer cell invasion and metastasis. Monomer and homodimer. Interacts with NuRD subcomplexes containing GATAD2A. Interacts with the histone deacetylase NuRD complex subunit CHD4; the interaction is direct, appears to occur with monomeric ZMYND8, and is increased following DNA damage. Interacts (via N-terminus) with the P-TEFb complex subunit CCNT1 (via central region); the interaction is direct and the association appears to occur between homodimeric ZMYND8 and the activated form of the P-TEFb complex. Interacts (via N-terminus) with DBN1 (via ADF-H domain); the interaction leads to sequestering of ZMYND8 in the cytoplasm. Interacts with the P-TEFb complex subunit CDK9; the association appears to occur between homodimeric ZMYND8 and the activated form of the P-TEFb complex. Interacts with EZH2; the interaction is dependent on the presence of chromatin. Interacts (via MYND domain) with the NuRD complex subunit GATAD2A. Interacts with histone H3 (via N-terminus) that is both methylated at 'Lys-4' (H3K4me1) and acetylated at 'Lys-14' (H3K14ac), with histone H3 (via N-terminus) unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-14' (H3K14ac), and with histone H3 (via N-terminus) di-methylated at 'Lys-36' (H3K36me2). Interacts (via Bromo domain) with histone H4 acetylated at 'Lys-16'. Interacts with HDAC1. Interacts with HDAC2. Interacts with KDM1A. Interacts with KDM5C. Interacts with KDM5D. Interacts in vitro with PRKCB. Interacts with RNA polymerase II subunit POLR2A phosphorylated at 'Ser-5'. Interacts with ZNF592. Interacts with ZNF687. Does not interact with GATAD2B. 2 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.

Alternate Names

CTCL tumor antigen se14-3; CTCL-associated antigen se14-3; cutaneous T-cell lymphoma associated antigen se14-3; Cutaneous T-cell lymphoma-associated antigen se14-3; KIAA1125; MGC31836; MYND-type zinc finger-containing chromatin reader ZMYND8; PKCB1; predicted protein of HQ2893; PRKCBP1; PRO2893; protein kinase C binding protein 1; Protein kinase C-binding protein 1; RACK7; zinc finger MYND domain containing protein 8; Zinc finger MYND domain-containing protein 8; zinc finger MYND-type containing 8; zinc finger, MYND-type containing 8; ZMYND8